D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
Pfizer
PFE
|
+$439M |
| 2 |
AbbVie
ABBV
|
+$401M |
| 3 |
Johnson & Johnson
JNJ
|
+$308M |
| 4 |
Gilead Sciences
GILD
|
+$261M |
| 5 |
Mercado Libre
MELI
|
+$259M |
Top Sells
| 1 |
Booking.com
BKNG
|
+$391M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$390M |
| 3 |
Citigroup
C
|
+$315M |
| 4 |
PayPal
PYPL
|
+$282M |
| 5 |
SHPG
Shire pic
SHPG
|
+$276M |
Sector Composition
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 16.79% |
| 3 | Healthcare | 16.62% |
| 4 | Financials | 9.01% |
| 5 | Industrials | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARQL
2026
DELISTED
Arqule Inc
ARQL
| $569K | ﹤0.01% |
118,701
-189,355
| -61% | -$908K |
|
2027
Fresenius Medical Care
FMS
$14.8B
| $568K | ﹤0.01% |
14,010
-197,754
| -93% | -$8.02M |
|
|
STKL
2028
SunOpta
STKL
$754M
| $568K | ﹤0.01% |
164,057
-47,214
| -22% | -$163K |
|
2029
Vanda Pharmaceuticals
VNDA
$270M
| $568K | ﹤0.01% |
+30,845
| New | +$568K |
|
2030
Towne Bank
TOWN
$2.85B
| $566K | ﹤0.01% |
22,875
-3,579
| -14% | -$88.6K |
|
2031
Xenon Pharmaceuticals
XENE
$2.87B
| $565K | ﹤0.01% |
55,632
-75,588
| -58% | -$768K |
|
2032
Park Aerospace
PKE
$377M
| $558K | ﹤0.01% |
35,558
+25,008
| +237% | +$392K |
|
2033
Topgolf Callaway Brands
MODG
$1.77B
| $555K | ﹤0.01% |
34,871
-44,636
| -56% | -$710K |
|
2034
Renasant Corp
RNST
$3.59B
| $554K | ﹤0.01% |
16,377
-21,065
| -56% | -$713K |
|
2035
Houlihan Lokey
HLI
$14.6B
| $553K | ﹤0.01% |
12,065
-25,654
| -68% | -$1.18M |
|
2036
Children's Place
PLCE
$161M
| $553K | ﹤0.01% |
5,689
-10,911
| -66% | -$1.06M |
|
2037
RLI Corp
RLI
$6.11B
| $553K | ﹤0.01% |
15,418
-18,066
| -54% | -$648K |
|
|
PGTI
2038
DELISTED
PGT, Inc.
PGTI
| $552K | ﹤0.01% |
+39,890
| New | +$552K |
|
2039
UMB Financial
UMBF
$9.23B
| $548K | ﹤0.01% |
8,550
-6,864
| -45% | -$440K |
|
|
NITE
2040
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
| $548K | ﹤0.01% |
+21,615
| New | +$548K |
|
2041
Gannett
GCI
$623M
| $547K | ﹤0.01% |
52,173
-66,006
| -56% | -$692K |
|
|
HT
2042
DELISTED
Hersha Hospitality Trust Priority Class A Common Shares of Beneficial Interest
HT
| $544K | ﹤0.01% |
31,737
+21,159
| +200% | +$363K |
|
|
BLMT
2043
DELISTED
BSB Bancorp, Inc.
BLMT
| $544K | ﹤0.01% |
+16,564
| New | +$544K |
|
2044
Ecolab
ECL
$77.5B
| $543K | ﹤0.01% |
3,075
-3,325
| -52% | -$587K |
|
|
RDS.B
2045
DELISTED
Royal Dutch Shell PLC ADS Class B
RDS.B
| $543K | ﹤0.01% |
8,492
+5,131
| +153% | +$328K |
|
2046
CorVel
CRVL
$4.52B
| $542K | ﹤0.01% |
24,945
+11,655
| +88% | +$253K |
|
2047
Cass Information Systems
CASS
$570M
| $541K | ﹤0.01% |
11,442
+6,348
| +125% | +$300K |
|
2048
Hannon Armstrong Sustainable Infrastructure Capital
HASI
$3.53B
| $539K | ﹤0.01% |
21,036
+10,131
| +93% | +$260K |
|
2049
Douglas Dynamics
PLOW
$763M
| $538K | ﹤0.01% |
+14,123
| New | +$538K |
|
2050
Dover
DOV
$24.4B
| $536K | ﹤0.01% |
+5,717
| New | +$536K |
|